Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 20c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($1.61), $0.20 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $0 versus the consensus estimate of $1.95 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Revolution (RVMD) PT Raised to $215 at Mizuho
• Z Squared (ZSQR) files mixed shelf
• Protagonist Therapeutics (PTGX) PT Raised to $145 at Truist Securities